UNION CITY, Calif.,
April 18, 2017 /PRNewswire/
-- Abaxis, Inc. (NasdaqGS: ABAX), a global diagnostics company
manufacturing point-of-care blood analysis instruments and
consumables for the medical and veterinary markets worldwide, has
scheduled a conference call to discuss its financial results for
the fourth quarter and fiscal year 2017, ended March 31, 2017. The call will be at 4:15 p.m. ET on Thursday,
April 27, 2017. The Company will report financial
results for the fourth quarter and fiscal year 2017 after the
market closes on Thursday, April 27,
2017.
Participants can dial (844) 855-9498 or (412) 317-5496 to access
the conference call, or can listen via a live Internet web cast,
which is available in the Investor Relations section of the
Company's website at www.abaxis.com. A replay of the call is
available by visiting www.abaxis.com for the next 30 days or by
calling (877) 344-7529 or (412) 317-0088, confirmation code
10105658, through May 4, 2017.
About Abaxis
Abaxis, Inc. is a worldwide developer,
manufacturer and marketer of portable blood analysis systems that
are used in a broad range of medical specialties in human or
veterinary patient care to provide clinicians with rapid blood
constituent measurements. Our mission is to improve the
efficiency of care delivery to and the quality of life of patients
in the medical and veterinary markets. We provide leading
edge technology and tools that support best medical practices,
enabling physicians and veterinarians to respond to the health
needs of their clients at the point of care while operating
economical and profitable practices. For more information,
visit http://www.abaxis.com.
Contact:
|
Clint
Severson
|
Lytham Partners,
LLC
|
|
Chief Executive
Officer
|
Joe Dorame, Joe Diaz
& Robert
Blum
|
|
Abaxis,
Inc.
|
602-889-9700
|
|
510-675-6500
|
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/abaxis-to-report-fourth-quarter-and-fiscal-year-2017-financial-results-on-thursday-april-27-2017-300441222.html
SOURCE Abaxis, Inc.